How effective is carbidopa/levodopa enteral suspension (Duopa) in increasing the benefit of levodopa in the treatment of Parkinson disease (PD)?

Updated: Jan 24, 2019
  • Author: Robert A Hauser, MD, MBA; Chief Editor: Selim R Benbadis, MD  more...
  • Print
Answer

In January 2015, the FDA approved a carbidopa/levodopa enteral suspension (Duopa) that is infused into the jejunum by a portable pump. The efficacy of the enteral suspension to decrease off-time and increase on-time was shown in a multicenter, international study. From baseline to 12 weeks, mean off-time decreased by 4.04 hours for 35 patients allocated to the levodopa/carbidopa intestinal group compared with a decrease of 2.14 hours for 31 patients allocated to immediate-release oral levodopa/carbidopa (p=0.0015). Mean on-time without troublesome dyskinesia increased by 4.11 hours in the intestinal gel group and 2.24 hours in the immediate-release oral group (p=0.0059). [55]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!